Study Defines Urologic Practice Patterns for Management of Superficial Bladder Cancer in USA
Tuesday, 13 January 2004
BERKELEY, CA (UroToday Inc.) - Significant numbers of complete response rates occur after BCG therapy of pT1 or CIS bladder cancers. How do urologists apply this observation? Dr. F. N. Joudi, with his associates at the University of Iowa, Iowa City, report their study of degree of clinical application of intravesical immunotherapy chemotherapy in the USA in the December 2003 edition of Urology.
read more
|
Fentanyl Patch Safe, Effective for Long-term Relief of Cancer Pain
Friday, 05 December 2003
NEW YORK (Reuters Health) - The transdermal therapeutic system-fentanyl (TTS-F) is a safe and effective long-term analgesic option for moderate to severe cancer pain, both in patients who have previously been given oral morphine and those who have not, according to results of a study conducted in Greece.
read more
|
'Papillary Urothelial Neoplasms of Low Malignant Potential' Proposed as Alternate Name for Small Superficial (Ta) Bladder Carcinomas
Wednesday, 03 December 2003
BERKELEY, CA (UroToday Inc.) - Pathological classification of superficial bladder tumours as pTa Grade 1 places them in the category of transitional cell carcinoma or TCC. These groups overall do have the potential to progress to muscle invasive disease.
read more
|
Glaxo Says Drug May Make Cancer a Stable Disease
Wednesday, 03 December 2003
LONDON (Reuters) - GlaxoSmithKline Plc's head of cancer research said on Wednesday a new drug in development had the potential to convert cancer into a chronic and stable disease for many patients.
read more
|
Surgeon Caseload Largely Explains Hospital Volume Link to Mortality
Wednesday, 26 November 2003
NEW YORK (Reuters Health) - Numerous reports have shown that operative mortality is lower at hospitals with high procedural volumes. Now, new research suggests that this association is largely mediated by the caseload of the operative surgeon.
read more
|
Anti-smoking Programs Underfunded, Group Says
Wednesday, 12 November 2003
WASHINGTON (Reuters) - States that cashed in on a landmark $246 billion settlement with tobacco companies 5 years ago are spending little on programs to curb smoking, an anti-smoking group charged on Wednesday.
read more
|
Fluid Intake Does not Affect Bladder Cancer Recurrence
Friday, 07 November 2003
NEW YORK (Reuters Health) - Although high fluid intake has been linked to a reduced risk of bladder cancer, new research suggests that it does not prevent the recurrence of this malignancy.
read more
|
Prompt Bladder Cancer Surgery Aids Disease Control
Thursday, 30 October 2003
NEW YORK (Reuters Health) - A delay of more than about 3 months before performing radical cystectomy for muscle invasive bladder cancer can result in greater pathology, researchers report in the October issue of the Journal of Urology.
read more
|
Modified Laparoscopic Nephroureterectomy Provides Benefits Over Open Nephroureterectomy and Results in no Increased Risk of Tumor Recurrence
Monday, 20 October 2003
Dr. H.C. Klingler and colleagues from Vienna, Austria write in the October issue of European Urology about their experience with 19 patients who underwent modified laparoscopic nephroureterectomies (LNU) and compared them to 15 who had standard open nephroureterectomies (ONU).
read more
|
Smoking Link May Explain Anti-bladder Cancer Effects of Vitamins
Friday, 10 October 2003
NEW YORK (Reuters Health) - A few reports have suggested that certain vitamins protect against bladder cancer. However, new study findings indicate that the apparent anti-cancer effect disappears after accounting for smoking history.
read more
|
Sigmoid Neovagina Can Allow Normal Sexual Function for Rokitansky Patients
Friday, 12 September 2003
NEW YORK (Reuters Health) - The creation of a neovagina with a sigmoid graft can allow normal sexual function for women with Rokitansky syndrome, an uncommon disorder characterized by congenital lack of a vagina and uterus, new research shows.
read more
|
Electromotive Acceleration Improves Mitomycin C Delivery for Bladder Cancer
Thursday, 04 September 2003
NEW YORK (Reuters Health) - As a treatment for high-risk superficial bladder cancer, electro-osmotic delivery of slightly ionized mitomycin C (MMC) achieves better bladder uptake and response rates than passive MMC, according to a report published in the September issue of Urology.
read more
|
Adding Chemotherapy to Surgery Improves Bladder Cancer Survival
Friday, 29 August 2003
NEW YORK (Reuters Health) - Giving chemotherapy before radical cystectomy seems to improve the survival of patients with locally advanced bladder cancer, according to a report published in the August 28th issue of The New England Journal of Medicine.
read more
|
Adding Chemotherapy to Surgery Improves Bladder Cancer Survival
Friday, 29 August 2003
NEW YORK (Reuters Health) - Giving chemotherapy before radical cystectomy seems to improve the survival of patients with locally advanced bladder cancer, according to a report published in the August 28th issue of The New England Journal of Medicine.
read more
|
Green Tea Derivative Inhibits Bladder Tumor Growth in Rats
Wednesday, 13 August 2003
NEW YORK (Reuters Health) - Intravesical instillation of epigallocatechin-3-gallate (EGCG), a chemical found in green tea, inhibits bladder tumor growth in rats, according to a report published in the September issue of The Journal of Urology.
read more
|
Spectrum Reports Promising Early Clinical Data For Bladder Cancer Drug
Wednesday, 11 June 2003
NEW YORK (Reuters Health) - Spectrum Pharmaceuticals Inc., formerly NeoTherapeutics Inc., said on Wednesday that the first five patients treated in a phase I/II trial of the company's superficial bladder cancer drug Eoquin have experienced complete tumor disappearance.
read more
|
Platinum-based Chemotherapy Improves Survival of Invasive Bladder Cancer
Thursday, 05 June 2003
NEW YORK (Reuters Health) - Platinum-based neoadjuvant therapy is associated with a significant survival benefit for patients with invasive bladder cancer, according to a report published in the June 7th issue of The Lancet. Platinum monotherapy, however, appears to offer no benefit.
read more
|
Mucin 7 Expression May Be Useful As Bladder Tumor Marker
Monday, 17 February 2003
NEW YORK (Reuters Health) - In voided urine samples, mucin 7 (MUC7) gene expression is highly sensitive and specific for the presence of bladder cancer, according to a recent report by German investigators.
read more
|
Adoptive Immunotherapy Shows Promise as Treatment for Bladder Cancer
Friday, 24 January 2003
NEW YORK (Reuters Health) - Adoptive immunotherapy with macrophage activated killer (MAK) cells appears to be a safe treatment for superficial bladder cancer that can reduce the risk of recurrence following resection, according to a recent report.
read more
|
Vitamin E Use Tied to Reduced Risk of Bladder Cancer Mortality
Friday, 13 December 2002
NEW YORK (Reuters Health) - People who take vitamin E regularly are less likely than those in the general population to die of bladder cancer, researchers report, but it is not clear if the vitamin itself or some lifestyle factor is responsible for the reduced risk.
read more
|
Arsenic Exposure May Lead to More Aggressive Bladder Cancers
Wednesday, 20 November 2002
NEW YORK (Reuters Health) - Bladder tumors that arise in patients exposed to high levels of arsenic demonstrate greater chromosomal instability than those that develop in patients exposed to lower levels, according to a report published in the November 20th issue of the Journal of the National Cancer Institute.
read more
|
Cigarette Smoking Confirmed as Risk for Urinary Bladder Cancer in Women
Friday, 15 November 2002
NEW YORK (Reuters Health) - Women who smoke significantly increase their risk for urinary bladder cancer, according to the results of a population-based study reported in the December 1st issue of Cancer.
read more
|
Multi-target Assay Better than Cytology in Detecting Recurrent Bladder Cancer
Tuesday, 05 November 2002
NEW YORK (Reuters Health) - A new multi-target DNA assay appears to be better than cytologic evaluation in detecting recurrent transitional cell cancer of the bladder, according to a report published in the November issue of The Journal of Urology.
read more
|
HER2 Expression Has Prognostic Importance in Advanced Bladder Cancer
Wednesday, 02 October 2002
NEW YORK (Reuters Health) - It may be worthwhile to test bladder tumors for HER2/neu expression, according to oncologists from the University of California Davis who have found that HER2/neu expression provides prognostic information for advanced urothelial carcinoma.
read more
|
Urine Microsatellite Instability Testing can Predict Bladder Cancer Recurrence
Tuesday, 24 September 2002
NEW YORK (Reuters Health) - Analyzing the genetic make-up of cells exfoliated in the urine for microsatellite instability (MSI) aids in the detection of superficial bladder tumors and in predicting recurrence of these tumors after resection, according to a report by French researchers.
read more
|
Immunocytologic Assays Better Than Current Tests at Detecting Bladder Cancer
Monday, 09 September 2002
NEW YORK (Reuters Health) - Monoclonal antibody-based immunocytology is superior to the two most widely accepted urine tests for detecting bladder cancer, study findings indicate.
read more
|
Gemcitabine Helpful in BCG-refractory Bladder Cancer
Tuesday, 13 August 2002
NEW YORK (Reuters Health) - Intravesical gemcitabine shows considerable action in bladder cancer patients who do not respond to intravesical instillation of Bacillus Calmette-Guerin (BCG), researchers report in the August 1st issue of the Journal of Clinical Oncology.
read more
|
Organ Preservation May be Alternative to Radical Cystectomy in Bladder Cancer
Thursday, 08 August 2002
NEW YORK (Reuters Health) - Ideal candidates for organ-sparing, combined-modality therapy of bladder cancer are patients with early-stage and unifocal tumors who have undergone a visibly complete trans-urethral resection (TUR) of their tumor, according to a report in the July 15th issue of the Journal of Clinical Oncology.
read more
|
Urine Assay for Mcm5 Protein Detects Bladder Cancer
Friday, 19 July 2002
NEW YORK (Reuters Health) - An immunofluorometric assay to measure a protein marker for DNA replication initiation may be better at catching early-stage bladder cancers than standard tests, UK researchers report in the July 17th issue of the Journal of the National Cancer Institute.
read more
|
Triple-modality Approach can Spare Bladder in Patients with Invasive Cancer
Wednesday, 17 July 2002
NEW YORK (Reuters Health) - A combination of tumor resection, chemotherapy and radiation for invasive bladder cancer allows bladder preservation in most patients, and the survival outcomes are comparable to those of radical cystectomy, according to a report published in the July issue of Urology.
read more
|
European Urology - Radical Cystectomy – Often Too Late? Yes, But …
Monday, 25 December 2006
Volume 50, Issue 6, Pages 1129-1138 (December 2006)Article Outline - The editors of European Urology elected to reprint this manuscript, which was initially published almost 20 yr ago and continues to contain important messages. Not only was the Mainz group one of the initiators advocating radical cystectomy as the optimal treatment for invasive bladder cancer, but they also made the following important points that are still true to this day.
read more
|
European Urology - Search for Biomarkers of Aggressiveness in Bladder Cancer
-
Volume 50, Issue 1, Pages 20-22 (July 2006) A noninvasive, highly accurate diagnostic test capable of predicting the probability of disease recurrence and progression has long been desired in the field of urologic oncology.
read more
|
Bladder Cancer 
